AgelessRx Broadens GLP-1 Weight Care Options to Advance Longevity-First Healthcare
ANN ARBOR, Mich.--(BUSINESS WIRE)-- AgelessRx, a pioneer in longevity and telehealth solutions, is expanding its suite of GLP-1 offerings to better serve customers seeking sustainable, medically guided solutions. The updated offering includes access to Zepbound® via LillyDirect® and the introduction of Compounded Liraglutide + B12.
This expansion reflects AgelessRx's mission to make science-backed, personalized longevity care more accessible, offering a range of clinically appropriate GLP-1 therapies that support better metabolic health and, in turn, potentially improve lifespan and healthspan.
Weight is one of the most modifiable risk factors affecting healthy aging. Elevated BMI is strongly associated with reduced life expectancy, insulin resistance, and age-related disease. For people who've struggled to achieve a lower BMI through lifestyle alone, GLP-1s have been a promising solution.
The GLP-1 category is projected to exceed $322.85 billion globally by 2034, with rapid growth at 21.3% CAGR, driven by public demand for obesity and metabolic health solutions that target the biology behind weight gain. As a longevity-first platform, AgelessRx is uniquely positioned to guide customers through safe, personalized use of these therapies as part of a broader preventative care model.
AgelessRx clinicians will evaluate eligibility and, if appropriate, prescribe Zepbound® for fulfillment via LillyDirect®, Eli Lilly's direct-to-patient pharmacy. AgelessRx will provide full prescription management and clinical oversight for $50/month, including titration guidance, side-effect monitoring, as well as ongoing care and education to provide an additional layer of longevity-focused support. If eligible, patients can access Zepbound® single-dose vials directly from LillyDirect®, starting at $349/month. AgelessRx is not affiliated with Eli Lilly or LillyDirect® and serves solely as the prescribing and care coordination provider to support patients through their treatment.
Recent topline results from the SURMOUNT-5 trial show the impact of Zepbound® (tirzepatide):
−20.2% average weight reduction with tirzepatide compared to -13.7% with semaglutide
47% greater relative reduction in weight
Over 31% of patients on tirzepatide achieved ≥25% weight loss
While full peer-reviewed results are pending, these findings reinforce growing evidence that dual GIP/GLP-1 receptor agonists like tirzepatide may offer significant metabolic benefits.
In addition to supporting access to Zepbound® via LillyDirect®, AgelessRx has also introduced Compounded Liraglutide + B12, a daily GLP-1 injectable. These two new treatments join several other metabolic health solutions, all of which are prescribed following a comprehensive evaluation and personalized plan, providing eligible customers with a diverse range of treatment options based on affordability, clinical fit, safety, and overall health goals.
For additional information about AgelessRx, please visit agelessrx.com.
*AgelessRx has no affiliation or partnership with Eli Lilly or LillyDirect®. AgelessRx's role is to provide clinical evaluation and prescription management for patients who meet the medical criteria for Zepbound®. Medication fulfillment is handled solely by LillyDirect®.
About AgelessRx
AgelessRx is at the forefront of the longevity revolution, offering clinically validated, cutting-edge solutions and preventive treatments aimed at extending life expectancy and enhancing quality of life. AgelessRx also continues to advance the field of longevity science by conducting ongoing research and clinical trials. Through its online platform, AgelessRx provides easy access to innovative healthcare services, with an emphasis on customer satisfaction, affordability, and the pursuit of a future where extended healthspan is a reality for everyone. Follow AgelessRx on Instagram, X, and Facebook.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12 hours ago
- Yahoo
Truist Reiterates Eli Lilly (LLY) Buy Rating on Orforglipron Diabetes Drug Data
Eli Lilly and Company (NYSE:LLY) is one of the 12 stocks that will make you rich in 10 years. On June 23, Truist Securities reiterated its 'Buy' rating on Eli Lilly stock. The firm also maintained the price target of $1,038.00. Truist's move followed Eli Lilly's presentation at the American Diabetes Association (ADA) 85th Annual Meeting. Pixabay/Public Domain The rating pertains to Eli Lilly's oral diabetes drug, orforglipron (OFG), evaluated in the Phase 3 ACHIEVE-1 study for Type 2 diabetes treatment. The ACHIEVE-1 study results were presented at the ADA conference, showcasing orforglipron's efficacy and safety profile. The trial demonstrated statistically significant reductions in A1C (a long-term blood sugar metric) and body weight compared to placebo, with efficacy increasing at higher doses. Truist's analysis was informed by attending the orforglipron presentation, gathering feedback from KOLs at the ADA conference, and participating in Eli Lilly's investor event, where management provided clarity to alleviate safety concerns. The firm noted that longer-term data are required to further strengthen orforglipron's safety profile, particularly for chronic use in diabetes and potential obesity indications. Eli Lilly and Company (NYSE:LLY) is an American global biopharmaceutical company. The company discovers, develops, and markets prescription medicines for diabetes, obesity, cancer, immunological disorders, and neurological diseases. Its key products include Mounjaro, Zepbound, Trulicity, Verzenio, Taltz, and Jardiance. While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None.
Yahoo
14 hours ago
- Yahoo
Citi Expresses Optimism for Eli Lilly and Company (LLY)
Eli Lilly and Company (NYSE:LLY) is one of the 13 Best Long Term Growth Stocks to Invest in Right Now. On June 25, Citi reported that 'compelling' data shows that Eli Lilly and Company (NYSE:LLY) and Novo Nordisk (NVO) have turned obesity into a treatable disease from a lifestyle-based condition. The firm models more than $40 billion in obesity sales by 2030, well above the consensus estimates of $25 billion. Citi stated that as the obesity space evolves from injectables to convenient orals, such as orforglipron, the emergence of a 'dynamic' consumer-centric market is possible, and LillyDirect by Eli Lilly and Company (NYSE:LLY) is well-positioned to connect high consumer visibility for orforglipron with global access. In a research note, Citi further stated that it estimated penetration rates via income-based tiers for pricing and out-of-pocket costs in low- and mid-body mass index patients. The results place Eli Lilly and Company's (NYSE:LLY) consumer platform opportunity at $15B, which is not assumed in the firm's model. It thus believes that Eli Lilly and Company's (NYSE:LLY) is in a position to expedite access outside the US, employing a centralized out-of-pocket payment model instead of the traditional country-by-country launch. It contended that an 'income-based tiered pricing of orforglipron via LillyDirect could unlock unprecedented volume, all the while allowing it to maintain overall pricing power.' Eli Lilly and Company (NYSE:LLY) develops, manufactures, discovers, and sells pharmaceutical products. These products span oncology, diabetes, immunology, neuroscience, and other therapies. Investors are bullish on Eli Lilly and Company (NYSE:LLY) due to its in-demand GLP-1 drugs, used to treat diabetes and obesity, which are still in their early growth stages, and the company's strong financials. While we acknowledge the potential of LKQ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
Yahoo
15 hours ago
- Yahoo
This Dirt Cheap Healthcare Stock Could Be a Hidden Artificial Intelligence (AI) Opportunity (Hint: It's Not Eli Lilly)
One major potential use case for AI in healthcare is drug discovery for pharmaceutical companies. Insurance is another healthcare-related industry likely to benefit from AI, which could aid scenario modeling, predictive analytics, and natural language processing. UnitedHealth Group experienced some operational challenges this year, but AI could wipe away these shortcomings in the long run. 10 stocks we like better than UnitedHealth Group › When it comes to popular healthcare stocks, investors have focused a lot of attention lately on Eli Lilly and Novo Nordisk and the potential of their blockbuster weight management treatments, including Mounjaro, Zepbound, Ozempic, and Wegovy. While these drugs are likely to lead to billions in revenue, Lilly and Novo aren't relying solely on these drugs to grow their businesses. Both companies are also looking into the potential that artificial intelligence (AI) can bring to their operations -- and for good reason. Accounting and consulting firm PwC estimates that the total addressable market (TAM) for AI in healthcare could reach $868 billion by 2030. One of the obvious applications that AI has for healthcare is facilitating pharmaceutical companies in clinical trials and drug discovery. While such use cases are exciting, I see another pocket of the healthcare industry that could be positively disrupted by AI: insurance. Let's explore why UnitedHealth Group (NYSE: UNH) could be an under-the-radar growth opportunity because of the intersection between healthcare and AI. Back in April, UnitedHealth greatly disappointed investors after the company published revised financial guidance that indicated a lower-than-expected earnings outlook for the remainder of the year. Management blamed the lower profitability on two primary factors. First, utilization rates in the company's Medicare Advantage program exceeded internal forecasts, taking a toll on the company's cost structure. Second, reimbursements in the company's pharmacy benefits management (PBM) platform, Optum Health, were negatively impacted by reductions in Medicare funding as well as changes to some of the patient demographic profiles in this segment of the business. In short order, the stock price plunged and has shown no indications of recovery, so far. For 2025, share prices are down 40%, making UnitedHealth the poorest-performing stock in the Dow Jones Industrial Average this year. But before you go writing UnitedHealth off as a broken business, let's examine how AI has the potential to help the health insurance industry and how UnitedHealth specifically could implement this technology to improve the business over time. The underlying issue surrounding UnitedHealth's challenges right now has to do with forecasting. There isn't anything fundamentally broken with the business. Rather, unforeseen changes in the macroeconomic environment led to a different reality than what management had previously modeled -- ultimately leading to higher costs and compressed profit margins. By using machine learning, UnitedHealth could train AI models on claims data and subsequently integrate these feeds into electronic health records (EHR) to help predict more accurate utilization trends. More efficient data feeds could help UnitedHealth hone its pricing strategy and better plan for cost spikes. In addition, AI has the ability to build predictive models that can more accurately assess patient risk profiles. In theory, this has the potential to analyze more granular detail around various segments of patient data as it relates to engagement rates and risk profiles. This could help improve reimbursement forecasts for the Optum business. Lastly, natural language processing (NLP) can also be used to create scenario models by simulating how a business could be impacted based on changes in the regulatory landscape. An example of a company that specializes in this area of AI training is FiscalNote. This could help UnitedHealth plan more strategically as it pertains to budgeting decisions during periods of political uncertainty. While shares of UnitedHealth trade at a slight premium to other large health insurers based on forward earnings multiples, the bigger takeaway from the trends below is that the stock price is hovering near a five-year low. While UnitedHealth's operational challenges won't be fixed overnight, it is key to remember that management believes the company can course correct throughout the second half of this year and be better positioned by 2026. Whether UnitedHealth transitions into an AI-powered service remains to be seen. Investors with a long-run time horizon might want to consider holding on to their shares, though, as the ideas explored above showcase how AI has the potential to become a game-changing advancement for the health insurance industry over time. Looked at a different way, UnitedHealth could transform its business over the next several years by making cognizant investments in this technology. Nevertheless, the stock appears dirt cheap right now, and I think patient investors will be rewarded as the company turns things around over the next couple of quarters. Before you buy stock in UnitedHealth Group, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and UnitedHealth Group wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $713,547!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $966,931!* Now, it's worth noting Stock Advisor's total average return is 1,062% — a market-crushing outperformance compared to 177% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 23, 2025 Fiscal Note is a transcription service used by The Motley Fool. Adam Spatacco has positions in Eli Lilly and Novo Nordisk. The Motley Fool recommends Novo Nordisk and UnitedHealth Group. The Motley Fool has a disclosure policy. This Dirt Cheap Healthcare Stock Could Be a Hidden Artificial Intelligence (AI) Opportunity (Hint: It's Not Eli Lilly) was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
